Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

Rossum, A.G.J. van; Kok, M.; Werkhoven, E. van; Opdam, M.; Mandjes, I.A.M.; Leeuwen-Stok, A.E. van; ... ; MATADOR Trialists' Grp (2018)

Article / Letter to editor

• Chemotherapy
• Breast cancer
• Dose-dense
• Taxane
• Efficacy
• Biomarker discovery

• All authors: Rossum, A.G.J. van; Kok, M.; Werkhoven, E. van; Opdam, M.; Mandjes, I.A.M.; Leeuwen-Stok, A.E. van; Tinteren, H. van; Imholz, A.L.T.; Portielje, J.E.A.; Bos, M.M.E.M.; Bochove, A. van; Wesseling, J.; Rutgers, E.J.; Linn, S.C.; Oosterkamp, H.M.; MATADOR Trialists' Grp
• Date: 2018-10-31
• Journal: European Journal of Cancer
• Volume: 102
• Pages: 40 - 48
• DOI: doi:10.1016/j.ejca.2018.07.013
• Link: https://reader.elsevier.com/reader/sd/pii/S0959804918309821?token=05263A...